Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 6/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16224793 | 0.86 | KDM4E (0.53) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL19303144 | 0.82 | ALDH1A1 (0.47) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL19772111 | 0.80 | KDM4E (0.48) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL22166117 | 0.80 | KCNH2 (0.47) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL27176834 | 0.74 | CCR1 (0.43) | CCR1TSHR | |
| SCHEMBL3967035 | 0.74 | KDM4E (0.56) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL30602400 | 0.74 | MBOAT4 (0.44) | ALDH1A1CCR1MBOAT4 | |
| SCHEMBL29130943 | 0.74 | MBOAT4 (0.44) | ALDH1A1CCR1MBOAT4 | |
| SCHEMBL30087197 | 0.74 | CCR1 (0.43) | CCR1TSHR | |
| SCHEMBL30640933 | 0.74 | CCR1 (0.43) | KDM4EALDH1A1L3MBTL1CCR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2119717-B1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2018-01-17 | — | — | EP | disclosed |
| US-9868748-B2 | Thiazolopyrrolidine inhibitors of ROR- γ | VITAE PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868748-B2 | Thiazolopyrrolidine inhibitors of ROR- γ | VITAE PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170008910-A1 | THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-01-12 | — | — | US | disclosed |
| US-20170008910-A1 | THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-01-12 | — | — | US | disclosed |
| EP-2991994-A1 | THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014179564-A1 | THIAZALOPYRROLIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179564-A1 | THIAZALOPYRROLIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| US-8697868-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-15 | — | — | US | disclosed |
| EP-2119717-A1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors | Boehringer Ingelheim International GmbH (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-1758905-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-7501426-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-10 | — | — | US | disclosed |
| EP-1758905-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2007-03-07 | — | — | EP | disclosed |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
| WO-2005085246-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DPP INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP7 | KDM4E 1036/4885ALDH1A1 276/4885MEN1 4401/4885 |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | DPP8, DPP4, DPP7 | KDM4E 1140/4885ALDH1A1 287/4885MEN1 3845/4885 |
| US-20170008910-A1 | THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | KDM4E 3572/4885ALDH1A1 194/4885MEN1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.